

Isabelle Huys

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4664284/publications.pdf>

Version: 2024-02-01

63
papers

1,647
citations

361045

20
h-index

344852

36
g-index

66
all docs

66
docs citations

66
times ranked

1636
citing authors

#	ARTICLE	IF	CITATIONS
1	Qualitative Analysis of the Design and Implementation of Benefit-Sharing Programs for Biologics Across Europe. <i>BioDrugs</i> , 2022, 36, 217-229.	2.2	15
2	Regulatory Information and Guidance on Biosimilars and Their Use Across Europe: A Call for Strengthened One Voice Messaging. <i>Frontiers in Medicine</i> , 2022, 9, 820755.	1.2	16
3	Digitizing the Informed Consent Process: A Review of the Regulatory Landscape in the European Union. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	7
4	Co-creation with research participants to inform the design of electronic informed consent. <i>Digital Health</i> , 2022, 8, 205520762211090.	0.9	3
5	Biosimilars in Belgium: a proposal for a more competitive market. <i>Acta Clinica Belgica</i> , 2021, 76, 441-452.	0.5	13
6	Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer. <i>Clinical and Translational Science</i> , 2021, 14, 47-53.	1.5	4
7	Patient perspectives regarding gene therapy in haemophilia: Interviews from the PAVING study. <i>Haemophilia</i> , 2021, 27, 129-136.	1.0	27
8	Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions. <i>Drug Discovery Today</i> , 2021, 26, 399-415.	3.2	20
9	A Look at the History of Biosimilar Adoption: Characteristics of Early and Late Adopters of Infliximab and Etanercept Biosimilars in Subregions of England, Scotland and Wales - A Mixed Methods Study. <i>BioDrugs</i> , 2021, 35, 75-87.	2.2	11
10	Use of Patient Preferences in Health Technology Assessment: Perspectives of Canadian, Belgian and German HTA Representatives. <i>Patient</i> , 2021, 14, 119-128.	1.1	23
11	Patient Preferences in Rare Diseases: A Qualitative Study in Neuromuscular Disorders to Inform a Quantitative Preference Study. <i>Patient</i> , 2021, 14, 601-612.	1.1	8
12	Informing Patients about Biosimilar Medicines: The Role of European Patient Associations. <i>Pharmaceuticals</i> , 2021, 14, 117.	1.7	30
13	Patient Preferences to Assess Value IN Gene Therapies: Protocol Development for the PAVING Study in Hemophilia. <i>Frontiers in Medicine</i> , 2021, 8, 595797.	1.2	8
14	A comprehensive review on non-clinical methods to study transfer of medication into breast milk â€” A contribution from the ConcePTION project. <i>Biomedicine and Pharmacotherapy</i> , 2021, 136, 111038.	2.5	19
15	Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 644187.	1.6	14
16	Off-Patent Biologicals and Biosimilars Tendering in Europeâ€”A Proposal towards More Sustainable Practices. <i>Pharmaceuticals</i> , 2021, 14, 499.	1.7	18
17	Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians. <i>Journal of Pharmaceutical Policy and Practice</i> , 2021, 14, 53.	1.1	7
18	Personalized and long-term electronic informed consent in clinical research: stakeholder views. <i>BMC Medical Ethics</i> , 2021, 22, 108.	1.0	15

#	ARTICLE	IF	CITATIONS
19	Patient preferences for gene therapy in haemophilia: Results from the PAVING threshold technique survey. <i>Haemophilia</i> , 2021, 27, 957-966.	1.0	14
20	Clinical Research in Neonates: Redesigning the Informed Consent Process in the Digital Era. <i>Frontiers in Pediatrics</i> , 2021, 9, 724431.	0.9	2
21	Strengthening the global network for sharing of marine biological collections: recommendations for a new agreement for biodiversity beyond national jurisdiction. <i>ICES Journal of Marine Science</i> , 2021, 78, 305-314.	1.2	12
22	Community pharmacists' preparedness for substituting biologics and dispensing biosimilars – Lessons learned from a multinational survey. <i>Exploratory Research in Clinical and Social Pharmacy</i> , 2021, 4, 100084.	0.6	2
23	Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care. <i>Frontiers in Pharmacology</i> , 2021, 12, 789640.	1.6	6
24	Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!. <i>BioDrugs</i> , 2020, 34, 159-170.	2.2	75
25	Cross-Border Access to Clinical Trials in the EU: Exploratory Study on Needs and Reality. <i>Frontiers in Medicine</i> , 2020, 7, 585722.	1.2	5
26	Practical Implications From European Hospital Pharmacists on Prospective Risk Assessment for Medicine Shortages. <i>Frontiers in Medicine</i> , 2020, 7, 407.	1.2	6
27	An overview of critical decision-points in the medical product lifecycle: Where to include patient preference information in the decision-making process?. <i>Health Policy</i> , 2020, 124, 1325-1332.	1.4	28
28	European Stakeholder Learnings Regarding Biosimilars: Part II – Improving Biosimilar Use in Clinical Practice. <i>BioDrugs</i> , 2020, 34, 797-808.	2.2	33
29	European Stakeholder Learnings Regarding Biosimilars: Part I – Improving Biosimilar Understanding and Adoption. <i>BioDrugs</i> , 2020, 34, 783-796.	2.2	39
30	Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany. <i>Pharmaceuticals</i> , 2020, 13, 324.	1.7	20
31	Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies. <i>Frontiers in Pharmacology</i> , 2020, 11, 594446.	1.6	21
32	Risks in Antibiotic Substitution Following Medicine Shortage: A Health-Care Failure Mode and Effect Analysis of Six European Hospitals. <i>Frontiers in Medicine</i> , 2020, 7, 157.	1.2	20
33	The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 734-755.	2.3	86
34	Sharing of Clinical Trial Data and Samples: The Cancer Patient Perspective. <i>Frontiers in Medicine</i> , 2020, 7, 33.	1.2	8
35	Views of European Drug Development Stakeholders on Treatment Optimization and Its Potential for Use in Decision-Making. <i>Frontiers in Pharmacology</i> , 2020, 11, 43.	1.6	14
36	Patient Centricity in Patient Preference Studies: The Patient Perspective. <i>Frontiers in Medicine</i> , 2020, 7, 93.	1.2	14

#	ARTICLE	IF	CITATIONS
37	An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?. <i>MABs</i> , 2020, 12, 1743517.	2.6	31
38	The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures. <i>Frontiers in Pharmacology</i> , 2020, 11, 591134.	1.6	44
39	Conducting Non-COVID-19 Clinical Trials during the Pandemic: Can Today's Learning Impact Framework Efficiency?. <i>European Journal of Health Law</i> , 2020, 27, 425-450.	0.1	8
40	Improving Patient Preference Elicitation by Applying Concepts From the Consumer Research Field: Narrative Literature Review. <i>Interactive Journal of Medical Research</i> , 2020, 9, e13684.	0.6	2
41	Implementation of Electronic Informed Consent in Biomedical Research and Stakeholders' Perspectives: Systematic Review. <i>Journal of Medical Internet Research</i> , 2020, 22, e19129.	2.1	43
42	A study protocol for quantifying patient preferences in neuromuscular disorders: a case study of the IMI PRÉFER Project. <i>Wellcome Open Research</i> , 2020, 5, 253.	0.9	4
43	What Does Society Value About Cancer Medicines? A Discrete Choice Experiment in the Belgian Population. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 895-902.	1.0	3
44	Information needs of physicians regarding the diagnosis of rare diseases: a questionnaire-based study in Belgium. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 99.	1.2	65
45	Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review. <i>Drug Discovery Today</i> , 2019, 24, 1324-1331.	3.2	90
46	Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2 – Biosimilar and Originator Etanercept in the Outpatient Setting. <i>BioDrugs</i> , 2019, 33, 299-306.	2.2	16
47	Protection of Phage Applications in Crop Production: A Patent Landscape. <i>Viruses</i> , 2019, 11, 277.	1.5	15
48	Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1 – Biosimilar and Originator Infliximab in the Hospital Setting. <i>BioDrugs</i> , 2019, 33, 285-297.	2.2	23
49	Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method Study. <i>Frontiers in Pharmacology</i> , 2019, 10, 1395.	1.6	48
50	Factors and situations influencing the value of patient preference studies along the medical product lifecycle: a literature review. <i>Drug Discovery Today</i> , 2019, 24, 57-68.	3.2	69
51	Noninvasive prenatal testing: a survey of young (future) parents in Flanders. <i>Personalized Medicine</i> , 2018, 15, 35-43.	0.8	4
52	The necessity for a European definition of drug shortages. <i>International Journal of Pharmacy Practice</i> , 2018, 26, 289-290.	0.3	3
53	Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists. <i>BioDrugs</i> , 2017, 31, 447-459.	2.2	65
54	The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape. <i>Frontiers in Pharmacology</i> , 2017, 8, 314.	1.6	80

#	ARTICLE	IF	CITATIONS
55	Innovative Approaches to Increase Access to Medicines in Developing Countries. <i>Frontiers in Medicine</i> , 2017, 4, 218.	1.2	41
56	Policies for biosimilar uptake in Europe: An overview. <i>PLoS ONE</i> , 2017, 12, e0190147.	1.1	153
57	Industry Perspectives on Market Access of Innovative Drugs: The Relevance for Oncology Drugs. <i>Frontiers in Pharmacology</i> , 2016, 7, 144.	1.6	7
58	Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies. <i>Frontiers in Pharmacology</i> , 2016, 7, 193.	1.6	65
59	Intellectual property policies in early-phase research in public-private partnerships. <i>Nature Biotechnology</i> , 2016, 34, 504-510.	9.4	14
60	Qualitative study on custodianship of human biological material and data stored in biobanks. <i>BMC Medical Ethics</i> , 2016, 17, 15.	1.0	12
61	Toward a European definition for a drug shortage: a qualitative study. <i>Frontiers in Pharmacology</i> , 2015, 6, 253.	1.6	44
62	Market access of cancer drugs in European countries: improving resource allocation. <i>Targeted Oncology</i> , 2014, 9, 95-110.	1.7	33
63	Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2